Denileukin diftitox: a concise clinical review

Denileukin diftitox (DAB389IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

[1]  F. Craig,et al.  Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. , 1993, Cancer research.

[2]  W. Bishai,et al.  Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. , 1987, Protein engineering.

[3]  T. Woodworth,et al.  Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Gordon,et al.  Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. , 1993, Leukemia & lymphoma.

[5]  A. Gottlieb,et al.  A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. , 2001, Journal of the American Academy of Dermatology.

[6]  T. Kuzel,et al.  Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. , 2001, Clinical lymphoma.

[7]  Michael L. Wang,et al.  Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Goud,et al.  Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin , 1985, The Journal of cell biology.

[9]  T. Strom,et al.  Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor- mediated action of a diphtheria toxin-related interleukin 2 fusion protein , 1988, The Journal of experimental medicine.

[10]  M. Holick,et al.  Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. , 1998, Journal of the American Academy of Dermatology.

[11]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Vieweg,et al.  Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hainsworth,et al.  A phase II trial of denileukin difititox-in previously treated, advanced non-small cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Ratain,et al.  Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. , 1998, Blood.

[15]  T. Strom,et al.  Protein Engineering of DAB‐IL‐2 Fusion Toxins to Increase Biologic Potency a , 1991, Annals of the New York Academy of Sciences.

[16]  R. Gartenhaus,et al.  A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Ritz,et al.  Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[18]  J. Reuben,et al.  Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. , 1992, Blood.

[19]  P. Bonventre,et al.  Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation , 1985, Infection and immunity.

[20]  S. Schmid,et al.  A possible role for Na+,K+-ATPase in regulating ATP-dependent endosome acidification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Prince,et al.  Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  T. Kuzel,et al.  Cutaneous T-Cell Lymphoma: A Paradigm for Biological Therapies , 2004, Leukemia & lymphoma.